Estadisticas : Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study

Gianni, L.
Visitas:212

88 ( Estados Unidos de América )

31 ( Hong kong )

29 ( Singapur )

14 ( Brasil )

8 ( Francia )

8 ( Letonia )

5 ( Canadá )

5 ( Reino Unido )

5 ( España )

2 ( Alemania )

2 ( Finlandia )

2 ( India )

2 ( Vietnam )

2 ( Arabia Saudita )

2 ( México )

1 ( Croacia )

1 ( Rusia )

1 ( Nueva Zelanda )

1 ( Tailandia )

1 ( Italia )

1 ( Ecuador )

1 ( Austria )

Descargas: 0